ArticleFrontiers in immunology2026
Case Report: Converting an immunologically "cold" tumor: exceptional response to cadonilimab plus chemotherapy in microsatellite-stable pancreatic cystadenocarcinoma.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pancreatic cancer (PC) remains largely refractory to immune checkpoint inhibitors (ICIs), especially in the prevalent microsatellite-stable (MSS) subtype. However, combination strategies of ICIs with chemotherapy have largely failed in MSS PC, highlighting an urgent need for novel immunotherapeutic approaches. Cadonilimab is a novel programmed death protein 1(PD-1)/cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) bispecific antibody designed to remodel the immunosuppressive tumor microenvironment. Case report description: We report an exceptional and durable response to cadonilimab plus chemotherapy in a patient with metastatic MSS pancreatic cystadenocarcinoma (PCAC). Microsatellite stability was shown by immunohistochemistry with intact expression of all four mismatch repair proteins (MLH1, MSH2, MSH6, PMS2) and confirmed by next-generation sequencing (NGS). Following disease progression on first-line gemcitabine/nab-paclitaxel and transarterial chemoembolization (TACE), the patient subsequently received second-line therapy with cadonilimab combined with nab-paclitaxel and oxaliplatin. Notably, within two months of treatment initiation, the patient achieved near-complete remission (near-CR) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria, with an 89.9% reduction in the sum of target lesion diameters. Despite discontinuing anticancer therapy after 4 cycles due to grade 3 bone marrow suppression, which subsequently evolved into and has been maintained as a complete response (CR) for over 30 months, with the primary endpoint of progression-free survival (PFS) not yet reached. Conclusion: This case provides pioneering clinical evidence that cadonilimab, in combination with chemotherapy, can induce profound and durable remission in MSS PCAC, challenging current paradigms of ICI resistance and supporting the further development of bispecific antibody strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.